The rational use of intravenous amiodarone in the perioperative period

Anesthesiology

Volumn 86, Issue 4, 1997, Pages 974-987

  Baiser, Jeffrey R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG USE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; INTENSIVE CARE; INTRAVENOUS ANESTHESIA; LUNG TOXICITY; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0030951686     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199704000-00028     Document Type: Article

References (83)

1. Mason JW: Amiodarone. N EngI J Med 1987; 316:455-65
2. Liberman BA, Teasdale SJ: Anaesthesia and amiodarone. Can Anaesth SocJ 1985; 32:629-38
3. Charlier R, Deltour G, Baudine A, Chaillet F: Pharmacology of amiodarone, an anti-anginal drug with a new biological profile. Arzneimittelforsch 1968; 18:1408-17
4. Charlier R: Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoreceptors. BrJ Pharmacol 1970; 39:668-74
5. Kosinski EJ, Albin JB, Young E, Lewis SM, Leland OS: Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 1984; 4:565-70
6. Singh BN: Amiodarone: historical development and pharmacologie profile. Am Heart J 1983; 106:788-97
7. Gloor HO, Urthaler F, James TN: Acute effects of amiodarone upon the canine sinus node and atrioventricular junctional region. J Clin Invest 1983; 71:1457-66
8. Mason JW, Hondegheni LM, Katzung BG: Amiodarone blocks inactivated cardiac sodium channels. Pflugers Arch 1983; 396:79-81
9. Mason JW, Hondeghem LM, Katzung BG: Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res 1984; 55:277-85
10. Baiser JR, Bennett PB, Hondeghem LM, Roden DM: Suppression of time-dependent outward current in guinea pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res 1991; 69:519-29
11. Yabek SM, Kato R, Singh BN: Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol 1986; 8:197-207
12. Mattioni TA, Zheutlin TA, Dunnington C, Kehoe RF: The proarrhythmic effects of amiodarone. Prog Cardiovasc Dis 1989; 31:439-46
13. + current: Differential sensitivity to block by Class III antiarrhythmic agents. J Gen Physiol 1990; 96:195-215
14. Morady F, DiCarlo LA, Krol RB, Baerman JM, de Buitleir M: Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 1986; 7:148-57
15. Ikeda N, Nademanee K, Kannan R, Singli B: Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J 1984; 108:890-8
16. Châtelain P, Laruel R: Amiodarone partitioning with phospholipid bilayers and erythrocyte membranes. J Pharm Sei 1985; 74:783-4
17. Holt DW, Tucker GT, Jackson PR, Storey GCA: Amiodarone pharmacokinetics. Am Heart J 1983; 106:840-7
18. Andreasen R, Agerbaek H, Bjerregaard P, Gotzsche H: Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981; 19:293-9
19. Rakita L, Sobol SM: Amiodarone in the treatment of refractory ventricular arrhythmias. Importance and safety of initial high-dose therapy. JAMA 1983; 250:193-5
20. Roden DM: Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993; 72:45F-50F
21. Naccarelli GV, Dougherty AH: Amiodarone: a review of its pharmacologie, antiarrhythmic, and adverse effects, Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management. Edited by Podrid PJ, Kowey PR. Baltimore, Williams and Wilkins, 1995, pp 434-49
22. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, Gomes JA, Woosley RL: Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996; 27:67-75
23. Naccarelli GV, Jalal S: Intravenous amiodarone: another option in the acute management of sustained ventricular tachyarrhythmias. Circulation 1995; 92:3154-5
24. Aravanis C, Papasteriades E, SteriotisJ: Acute thrombophlebitis due to intravenous use of amiodarone. Chest 1982; 82:515-6
25. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, ChUson DA, Platia EV, Wilber DJ, Kowey PR: Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995; 92:3264-72
26. Perry JC, Knilans TK, Marlow D, Denfield SW, Fenrich AL, Friedman RA: Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults. J Am Coll Cardiol 1993; 22:95-8
27. Flanagan RJ, Storey GCA, Holt DW, Farmer PB: Identification and measurement of desethylamiodarone in blook plasma specimens from amiodarone treated patients. J Pharm Pharmacol 1982; 34:638-43
28. Nattel S, Davies M, Quantz M: The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 1988; 77:200-8
29. Prescribing Information: Cordarone® I.V. (amiodarone HCL), Wyeth-Ayerst Laboratories. Wyeth-Ayerst Laboratories, 1995
30. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM: Randomized, doubleblind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995; 92:3255-63
31. liedell SE, Delbanco TL, Cook EF, Epstein FH: Survival after cardiopulmonary resuscitation in the hospital. N Engl J Med 1983; 309:569-76
32. Urberg M, Ways C: Survival after cardiopulmonary resuscitation for an in-hospital cardiac arrest. J Fani Pract 1987; 25:41-4
33. Holt AW: Hemodynamic responses to amiodarone in critically ill patients receiving catecholamine infusions. Crit Care Med 1989; 17:1270-6
34. Oclii RP, Goldenberg IF, Almquist A, Pritzker M, Milstein S, Pedersen W, Gobel FL, Benditt DG: Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrthythmias in critically ill patients with coronary artery disease. Am J Cardiol 1989; 64:599-603
35. Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DM: Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamidc and amiodarone. Intensive Care Med 1993; 19:48-52
36. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P: Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med 1995; 23:1816-24
37. Crcsswcll IX, Schcussler RB, Rosenbloom M, Cox JL: Hazards of postoperative atrial arrhythmias. Ann Tliorac Surg 1993; 56:539-49
38. Installe E, Schoevaerdts JC, Gadisseux P, Charles S, Tremouroux J: Intravenous amiodarone in the treatment of various arrhythmias following cardiac operations. J Thorac Cardiovasc Surg 1981; 81:302-8
39. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ: Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Intern Med 1987; 106:503-6
40. Cochrane AD, Siddins M, Rosenfeldt FL, Salamonsen R, McConaghy L, Marasco S, Davis BB: A comparison of amiodarone and digoxin for treatment of supravcntricular arrhythmias after cardiac surgery. Eur J Cardiothorac Surg 1994; 8:194-8
41. McAlister HF, Luke RA, Whitlock RM, Smith WM: Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Tliorac Cardiovasc Surg 1990; 99:911-8
42. Hohnloser SH, Meinertz T, Dammbacher T, Steiert K, Jahnclien E, Zehender M, Fraedrich G, Just H: Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J 1991; 121:89-95
43. Butler J, Harriss DR, Sinclair M, Westaby S: Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomized, double blind, placebo controlled trial. Br Heart J 1993; 70:56-60
44. Laub GW, Janeira L, Muralidharan S, Riebman JB, Chen C, Neary M, Fernandez J, Adkins MS, McGrath LB: Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: a prospective, double-blind, randomized, placebo-controlled pilot study. Crit Care Med 1993; 21:1474-8
45. King FG, Addetia AM, Peters SD, Peachey GO: Prophylactic lidocaine for postoperative coronary artery bypass patients, a doubleblind, randomized trial. Can J Anaesth 1990; 37:363-8
46. Elami A, Merin G, Flugelman MY, Lyorit A, Rudis E, Halon DA, Lewis BS: Usefulness of late potentials on the immediate postoperative signal-averaged electrocardiogram in predicting ventricular tachyarrhythmias early after isolated coronary artery bypass grafting. AmJ Cardiol 1994; 74:33-7
47. Juneja R, Mehta Y, Trehan N: Prophylactic lidocaine hydrochloride does not reduce ventricular arrhythmias after coronary arterybypass grafting in patients with poor left ventricular function. Indian Heart J 1993:45:483-7
48. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333:77-82
49. Topol EJ, Lerman BB, Baughman KL, Platia EV, Griffith LSC: De novo refractor ventricular tachyarrhythmias after coronary revascularization. AmJ Cardiol 1986; 57:57-9
50. Raeder EA, Podrid PJ, Lown B: Side effects and complications of amiodarone therapy. Am Heart J 1985; 109:975-83
51. Dusman RE, Stantdn MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, Heger JJ: Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51-9
52. Hawthorne HR, Wood MA, Stambler BS, Damiano RJ, Ellenbogen KA: Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation? PACE 1993; 16:2241-9
53. Greenspon AJ, Kidwell GA, Hurley W, Mannion J: Amiodarone-related postoperative adult respirator)- distress syndrome. Circulation 1991; 84:407-15
54. Chelimsky-Fallick C, Middlekauff HR, Stevenson WG, Kobashigawa J, Saxon LA, Moriguchi J, Brownfield ED, Hamilton MA, Drinkwater D, Laks H, Stevenson IAV: Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol 1992; 20:1556-61
55. Mickleborough LL, Maruyama H, Mohamed S, Rappaport DC, Downar E, Butany J, Sun Z: Are patients receiving amiodarone at increased risk for cardiac operations? Ann Thorac Surg 1994; 58:622-9
56. Tuzcu EM, Maloney JD, Sangani BH, Masterson ML, Hocevar KD, Golding LAR, Starr NJ, Golish JA, Castle IAV, Morant VA: Cardiopulmonar)' effects of chronic amiodarone therapy in the early postoperative couse of cardiac surgery patients. Cleve Clin J Med 1987; 54:491-5
57. Nalos PC, Kass RM, Gang ES, Fishbein MC, Mandel WJ, Peter T: Life-threatening postoperative pulmonary complications in patients with previous amiodarone pulmonary toxicity undergoing cardiothoracic operations. J Thorac Cardiovasc Surg 1987; 93:904-12
58. MacKinnon G, Landymore R, Marble A: Should oral amiodarone be used for sustained ventricular tachycardia in patients requiring open-heart surgery. Can J Surg 1983; 26:355-7
59. Van Dyck M, Baele P, Rennotte T, Malta A, Dion R, KestensServaye Y: Should amiodarone be discontinued before cardiac surgery. Acta Anaesth Belg 1988; 39:3-10
60. Kirklin JW, Kirklin JK, Lell WA: Cardiopulmonary bypass for cardiac surgery, Gibbon's Surgery of the Chest. Edited by Sabiston DC, Spencer FC. Philadelphia, WB Saunders, 1983, pp 909
61. Kay NG, Epstein AE, Kirklin JK, Diethelm AG, Graybar G, Plumb VJ: Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 1988; 62:490-2
62. Van Mieghem W, Coolen L, Malysse I, Lacquet LM, Deneffe GJD, Demedts MGP: Amiodarone and the development of ARDS after lung surgery. Chest 1994; 105:1642-5
63. Martin WJ, Rosenow EC: Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 1). Chest 1988; 93:1067-75
64. Martin WJ, Rosenow EC: Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest 1988; 93:1242-8
65. Mathru M, McDaniel LB: Editorial: Priminn Non Nocere; Is the therapy worse than the disease. Chest 1994; 105:1634-6
66. Lapinsky SE, Mullen JBM, Balter MS: Rapid pulmonary phospholipid accumulation induced by intravenous amiodarone. Can J Cardiol 1993; 9:322-4
67. Kennedy JI, Myers JL, Plumb VJ, FulmerJD: Amiodarone pulmonary toxicity. Clinical, radiologie, and pathologic correlations. Arch Intern Med 1987; 147:50-5
68. Zeldin RA, Normandin D, Landtwin GD, Peters RM: Post-pneu-monectomy pulmonary edema. J Thorac Cardiovasc Surg 1984; 87:359-65
69. van der Zeijden H: Amiodarone and the development of ARDS after lung surgery (letter). Chest 1995; 107:885
70. Van Mieghem W: Amiodarone and the development of ARDS after lung surgery (letter). Chest 1995; 107:885-6
71. Gallagher JD, Lieberman RW, Meranze J, Spielman SR, Ellison N: Amiodarone-induced complications during coronary artery surgery. ANESTIIESIOLOGY 1981; 55:186-8
72. Navalgund AA, Alifimoff JK, Jakymec AJ, Bleyaert AL: Amiodarone-induced sinus arrest successfully treated with ephedrine and isoproterenol. Anesth Analg 1986; 65:414-6
73. Smiley RM, VuIIiemoz Y: Cardiac surgery causes desensitization of the β-adrenergic receptor system of human lymphocytes. Anesth Analg 1992; 74:212-8
74. Schwinn DA, Leone BJ, Spahn DR, Chesnut LC, Page SO, McRae RL, Liggett SB: Desensitization of myocardial β-adrenergic receptors during cardiopulmonary bypass: evidence for early uncoupling and late downregulation. Circulation 1991; 84:2559-67
75. Rooney RT, Marijic J, Stommel KA, Bosnjak ZJ, Aggarwal A, Kampine JP, Stowe DF: Additive cardiac depression by volatile anesthetics in isolated hearts after chronic amiodarone treatment. Anesth Analg 1995; 80:917-24
76. Michat L, Babrol C, Mattel MF, Gobin F, Bourel LM: Effets antiarythmiques de l'amiodarone injectable en reanimation de chirurgie cardio-vasculaire. Nouv Presse Med 1976; 5:1996
77. Roden DM, Woosley RL, Primm K: Incidence of clinical features of the quinidine associated long QT syndrome. Implications for patient care. Am Heart J 1986; 111:1088-93
78. Anderson JL: Sotalol, bretylium, and other class 3 antiarrhythmic agents, Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management. Edited by Podrid PJ, Kowey PR. Baltimore, Williams and Wilkins, 1995, pp 450-66
79. Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF: Amiodarone in patients with previous drug-mediated Torsade de Pointes. Ann Intern Med 1989; 111:574-80
80. Lazzara R: Amiodarone and torsade de pointes. Ann Intern Med 1989; 111:549-51
81. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R: Bradycardia-dependent triggered activity: relevance to drug-induced muliform ventricular tachycardia. Circulation 1983; 68:846-56
82. Roden DM, Hoffman BF: Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985; 56:857-67
83. Priori SG, Diehl L, Schwanz PJ: Torsade de Pointes, Cardiac arrhythmia: mechanisms, diagnosis, and management. Edited by Podrid PJ, Kowey PR. Baltimore, Williams and Wilkins, 1995, pp 951-63